Aggression is among the most common indications for referral to child and adolescent mental health services and is often challenging to treat. Understanding the biological underpinnings of aggression could help optimize treatment efficacy. Neuronal nicotinic acetylcholine receptors (nAChRs), specifically the α7 nAChR, encoded by the gene CHRNA7, have been implicated in aggressive behaviors in animal models as well as humans. Copy number variants (CNVs) of CHRNA7 are found in individuals with neuropsychiatric disorders, often with comorbid aggression. In this study, we aimed to determine the prevalence of CHRNA7 CNVs among individuals treated with risperidone, predominantly for irritability and aggression.
Methods:
Risperidone-treated children and adolescents were assessed for CHRNA7 copy number state using droplet digital PCR and genomic quantitative PCR. Demographic, anthropometric, and clinical data, including the Child Behavior Checklist (CBCL), were collected and compared across individuals with and without the CHRNA7 deletion.
Results:
Of 218 individuals (90% males, mean age: 12.3 ± 2.3 years), 7 (3.2%) were found to carry a CHRNA7 deletion and one proband carried a CHRNA7 duplication (0.46%). T-scores for rule breaking, aggression, and externalizing behavior factors of the CBCL were higher in the deletion group, despite taking 58% higher dose of risperidone.
Conclusions:
CHRNA7 loss may contribute to a phenotype of severe aggression. Given the high prevalence of the deletion among risperidone-treated youth, future studies should examine the therapeutic potential of α7 nAChR-targeting drugs to target aggression associated with CHRNA7 deletions.
Get full access to this article
View all access options for this article.
References
1.
AchenbachTM, McConaughySH, IvanovaMY, RescorlaLA: Manual for the ASEBA Brief Problem Monitor™ (BPM). Burlington, VT: University of Vermont Research Center for Children, Youth, and Families, 2001.
2.
BahrSM, TylerBC, WooldridgeN, ButcherBD, BurnsTL, TeeschLM, OltmanCL, Azcarate-PerilMA, KirbyJR, CalargeCA: Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Transl Psychiatry, 5:e652, 2015.
CalargeC, BurnsT, SchlechteJ, ZemelB: Longitudinal examination of the skeletal effects of selective serotonin reuptake inhibitors and risperidone in boys. J Clin Psychiatry, 76:607–613, 2015a.
5.
CalargeC, NicolG, SchlechteJ, BurnsT: Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment. J Child Adolesc Psychopharmacol, 24:120–129, 2014.
6.
CalargeC, SchlechteJ: Bone Mass in Boys with Autism Spectrum Disorder. J Autism Dev Disord, 47:1749–1755, 2017.
7.
CalargeC, SchlechteJ, BurnsT, ZemelB: The effect of psychostimulants on skeletal health in boys co-treated with risperidone. J Pediatrics, 166:1449.e1–1454.e1, 2015b.
8.
CubellsJ, DeoreoE, HarveyP, GarlowS, GarberK, AdamM, MartinC: Pharmaco-genetically guided treatment of recurrent rage outbursts in an adult male with 15q13.3 deletion syndrome. Am J Med Genet A, 155:805–810, 2011.
9.
FarmerC, AmanM: Aggressive behavior in a sample of children with autism spectrum disorders. Res Autism Spect Dis, 5:317–323, 2011.
10.
GeeK, OlincyA, KannerR, JohnsonL, HogenkampD, HarrisJ, TranM, EdmondsS, SauerW, YoshimuraR, JohnstoneT, FreedmanR: First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: Pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288. J Psychopharmacol, 31:434–441, 2017.
11.
GillentineMA, BerryLN, Goin-KochelRP, AliMA, GeJ, GuffeyD, RosenfeldJA, HannigV, BaderP, ProudM, ShinawiM, GrahamBH, LinA, LalaniSR, ReynoldsJ, ChenM, GrebeT, MinardCG, StankiewiczP, BeaudetAL, SchaafCP: The cognitive and behavioral phenotypes of individuals with CHRNA7 duplications. J Autism Dev Disord, 47:549–562, 2017.
12.
GillentineMA, SchaafCP: The human clinical phenotypes of altered CHRNA7 copy number. Biochem Pharmacol, 97:352–362, 2015.
Hoppman-ChaneyN, WainK, SegerP, SuperneauD, HodgeJ: Identification of single gene deletions at 15q13.3: Further evidence that CHRNA7 causes the 15q13.3 microdeletion syndrome phenotype. Clin Genet, 83:345–351, 2013.
15.
International Schizophrenia Consortium: Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature, 455:237–241, 2008.
16.
JensenP, YoungstromE, SteinerH, FindlingR, MeyerR, MaloneR, CarlsonG, CoccaroE, AmanM, BlairJ, DoughertyD, FerrisC, FlynnL, GreenE, HoagwoodK, HutchinsonJ, LaughrenT, LeveL, NovinsD, VitielloB: Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry implications for medication studies. J Am Acad Child Adolesc Psychiatry, 46:309–322, 2007.
17.
LewisAS, MineurYS, SmithPH, CahuzacEL, PicciottoMR: Modulation of aggressive behavior in mice by nicotinic receptor subtypes. Biochem Pharmacol, 97:488–497, 2015.
18.
LowtherC, CostainG, StavropoulosD, MelvinR, SilversidesC, AndradeD, SoJ, FaghfouryH, LionelA, MarshallC, SchererS, BassettA: Delineating the 15q13.3 microdeletion phenotype: A case series and comprehensive review of the literature. Genet Med, 17:149–157, 2015.
19.
MalhotraD, SebatJ: CNVs: Harbingers of a rare variant revolution in psychiatric genetics. Cell, 148:1223–1241, 2012.
OgdenCL, KuczmarskiRJ, FlegalKM, MeiZ, GuoS, WeiR, Grummer-StrawnLM, CurtinLR, RocheAF, JohnsonCL: Centers for Disease Control and Prevention 2000 growth charts for the United States: Improvements to the 1977 National Center for Health Statistics version. Pediatrics, 109:45–60, 2002.
24.
OlincyA, Blakeley-SmithA, JohnsonL, KemWR, FreedmanR: Brief report: Initial trial of alpha7-nicotinic receptor stimulation in two adult patients with autism spectrum disorder. J Autism Dev Disord, 46:3812–3817, 2016.
25.
PicciottoMR, LewisAS, van SchalkwykGI, MineurYS: Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states. Neuropharmacology, 96:235–243, 2015.
26.
ShafferD, FisherP, LucasCP, DulcanMK, Schwab-StoneME: NIMH diagnostic interview schedule for children version IV (NIMH DISC-IV): Description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry, 39:28–38, 2000.
27.
ShenJX, YakelJL: Nicotinic acetylcholine receptor-mediated calcium signaling in the nervous system. Acta Pharmacol Sin, 30:673–680, 2009.
28.
ShinawiM, SchaafCP, BhattSS, XiaZ, PatelA, CheungSW, LanpherB, NaglS, HerdingHS, Nevinny-StickelC, ImmkenLL, PatelGS, GermanJR, BeaudetAL, StankiewiczP: A small recurrent deletion within 15q13.3 is associated with a range of neurodevelopmental phenotypes. Nat Genet, 41:1269–1271, 2009.
29.
SteinerH, RemsingL: Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry, 46:126–141, 2007.
30.
Van BonBW, MeffordHC, MentenB, KoolenDA, SharpAJ, NillesenWM, InnisJW, de RavelTJ, MercerCL, FicheraM, StewartH, ConnellLE, OunapK, LachlanK, CastleB, Van der AaN, van RavenswaaijC, NobregaMA, Serra-JuhéC, SimonicI, de LeeuwN, PfundtR, BongersEM, BakerC, FinnemoreP, HuangS, MaloneyVK, CrollaJA, van KalmthoutM, EliaM, VandeweyerG, FrynsJP, JanssensS, FouldsN, ReitanoS, SmithK, ParkelS, LoeysB, WoodsCG, OostraA, SpelemanF, PereiraAC, KurgA, WillattL, KnightSJ, VermeeschJR, RomanoC, BarberJC, MortierG, Pérez-JuradoLA, KooyF, BrunnerHG, EichlerEE, KleefstraT, de VriesBB: Further delineation of the 15q13 microdeletion and duplication syndromes: A clinical spectrum varying from non-pathogenic to a severe outcome. J Med Genet, 46:511–523, 2009.
31.
VuTH, CoccaroEF, EichlerEE, GirirajanS: Genomic architecture of aggression: Rare copy number variants in intermittent explosive disorder. Am J Med Genet B Neuropsychiatr Genet, 156B:808–816, 2011.
32.
WilliamsNM, FrankeB, MickE, AnneyRJ, FreitagCM, GillM, ThaparA, O'DonovanMC, OwenMJ, HolmansP, KentL, MiddletonF, Zhang-JamesY, LiuL, MeyerJ, NguyenTT, RomanosJ, RomanosM, SeitzC, RennerTJ, WalitzaS, WarnkeA, PalmasonH, BuitelaarJ, RommelseN, VasquezAA, HawiZ, LangleyK, SergeantJ, SteinhausenH-CC, RoeyersH, BiedermanJ, ZaharievaI, HakonarsonH, EliaJ, LionelAC, CrosbieJ, MarshallCR, SchacharR, SchererSW, TodorovA, SmalleySL, LooS, NelsonS, ShtirC, AshersonP, ReifA, LeschK-PP, FaraoneSV: Genome-wide analysis of copy number variants in attention deficit hyperactivity disorder: The role of rare variants and duplications at 15q13.3. Am J Psychiatry, 169:195–204, 2012.
33.
WilliamsNM, ZaharievaI, MartinA, LangleyK, MantripragadaK, FossdalR, StefanssonH, StefanssonK, MagnussonP, GudmundssonOO, GustafssonO, HolmansP, OwenMJ, O'DonovanM, ThaparA: Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: A genome-wide analysis. Lancet, 376:1401–1408, 2010.
34.
ZahrtDM, Melzer-LangeMD: Aggressive behavior in children and adolescents. Pediatr Rev, 32:325–332, 2011.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
